Author Archives: Iqra Mumal, MSc

FDA Approves Zephyr Valve for Patients with Severe Emphysema

The U.S. Food and Drug Administration (FDA) has approved Pulmonx’s Zephyr Endobronchial Valve, a device designed to treat patients with severe emphysema who experience difficulty breathing. Emphysema is a type of chronic obstructive pulmonary disease (COPD) that results from damage to the alveoli, the small air sacs in…

UK Adds Endobronchial Valves to Standard of Care for Severe Emphysema

The U.K.’s National Institute for Health and Care Excellence (NICE) has updated its guidelines to include endobronchial valves as an appropriate routine treatment for severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD). This announcement comes on the heels of positive safety and effectiveness data from multiple…

Study Examines Global Disease Burden of COPD and Asthma

A new study highlights the significant global burden of chronic obstructive pulmonary disease (COPD) and asthma, and calls for more attention in the prevention and treatment of these conditions. The study titled “Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for…

Switching from Seretide to Ultibro Breezhaler Seen to Be Safe, Effective in COPD Patients

Results from Novartis’ FLASH clinical trial show that switching patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) from treatment with Seretide to Ultibro Breezhaler improved lung function. Ultibro Breezhaler was also found to be well-tolerated by patients. Seretide is an inhaled corticosteroid, and its long-term use can be associated with several side…